Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Could Agomelatine Play a Role to Treat Anhedonia in Heroin Dependence?

Could Agomelatine Play a Role to Treat Anhedonia in Heroin Dependence? Anhedonia is defined as a diminished ability to experience interest or pleasure, and is a critical psychopathologic dimension of major depressive disorder and is a commonly reported symptom among substance-dependent populations inside heroin addiction. The purpose of this report is to review the clinical evidence for the potential role of agomelatine to treat anhedonia in heroin dependence and literature review. We conducted a systematic review of the literature with the principal database (PubMed, Enbase, and PsychInfo) and we present a case report. Agomelatine was shown to be effective on anhedonia, depression, and anxiety in a subject with heroin dependence. The favorable effect of agomelatine on circadian rest-activity/sleep-wake cycle and on both depressive and anxiety symptoms is well knowed. To our knowledge in the literature there are no studies about the use of agomelatine to treat anhedonia in heroin addictated patient. We have any particular side effect and agomelatine was good tolerated. Further research is warranted to replicate our clinical and qualitative observations and, in general, quantitative studies in large samples followed up over time are needed. Methodological limitations, clinical implications, and suggestions for future research directions are considered. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Addictive Disorders & Their Treatment Wolters Kluwer Health

Could Agomelatine Play a Role to Treat Anhedonia in Heroin Dependence?

Addictive Disorders & Their Treatment , Volume Publish Ahead of Print – Jan 27, 2021

Loading next page...
 
/lp/wolters-kluwer-health/could-agomelatine-play-a-role-to-treat-anhedonia-in-heroin-dependence-A8v8kEX7HT

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1531-5754
eISSN
1535-1122
DOI
10.1097/ADT.0000000000000245
Publisher site
See Article on Publisher Site

Abstract

Anhedonia is defined as a diminished ability to experience interest or pleasure, and is a critical psychopathologic dimension of major depressive disorder and is a commonly reported symptom among substance-dependent populations inside heroin addiction. The purpose of this report is to review the clinical evidence for the potential role of agomelatine to treat anhedonia in heroin dependence and literature review. We conducted a systematic review of the literature with the principal database (PubMed, Enbase, and PsychInfo) and we present a case report. Agomelatine was shown to be effective on anhedonia, depression, and anxiety in a subject with heroin dependence. The favorable effect of agomelatine on circadian rest-activity/sleep-wake cycle and on both depressive and anxiety symptoms is well knowed. To our knowledge in the literature there are no studies about the use of agomelatine to treat anhedonia in heroin addictated patient. We have any particular side effect and agomelatine was good tolerated. Further research is warranted to replicate our clinical and qualitative observations and, in general, quantitative studies in large samples followed up over time are needed. Methodological limitations, clinical implications, and suggestions for future research directions are considered.

Journal

Addictive Disorders & Their TreatmentWolters Kluwer Health

Published: Jan 27, 2021

There are no references for this article.